Tandem Diabetes Care (TNDM) Common Equity (2013 - 2026)

Tandem Diabetes Care has reported Common Equity for 14 years, with the latest figure at $132.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 14.74% year-over-year to $132.4 million; the trailing twelve-month figure through Mar 2026 stood at $132.4 million (down 14.74% YoY), and the FY2025 full-year result was $155.2 million, down 41.02% from the prior year.
• Common Equity for Q1 2026 stood at $132.4 million, down from $155.2 million in the prior quarter.
• The five-year high for Common Equity was $449.6 million in Q2 2022, with the low at $132.4 million in Q1 2026.
• Historically, Common Equity has averaged $278.3 million across 5 years, with a median of $263.1 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity soared 39.55% — and 2025, when it plunged 44.06%.
• Tandem Diabetes Care's Common Equity stood at $439.9 million in 2022, then slipped by 28.71% to $313.6 million in 2023, then decreased by 16.11% to $263.1 million in 2024, then slumped by 41.02% to $155.2 million in 2025, then fell by 14.67% to $132.4 million in 2026.
• The last three Common Equity figures came in at $132.4 million (Q1 2026), $155.2 million (Q4 2025), and $133.0 million (Q3 2025), per Business Quant data.